ACL » Topics » Natural

This excerpt taken from the ACL 20-F filed Mar 18, 2008.
Natural, the AcrySof® IQ and the AcrySof® ReSTOR®.

 

62

The AcrySof® IQ is an aspheric lens that is designed to reduce corneal spherical aberration. After submitting clinical data on this lens to the CMS, effective May 19, 2006, this agency recognized the AcrySof® IQ intraocular lens as belonging to the NTIOL classification defined by Reduced Spherical Aberration. This NTIOL designation increases the Medicare payment to ambulatory surgery centers for cataract surgery by $50 when surgery is performed with an AcrySof® IQ intraocular lens. This NTIOL subset and adjusted payment for the AcrySof® IQ remain in effect until February 27, 2011.

 

The AcrySof® ReSTOR® lens was approved by the FDA in late March 2005. The AcrySof® ReSTOR® uses a proprietary apodized diffractive refractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery. Largely due to its U.S. launch in May 2005, global sales of AcrySof® ReSTOR® grew 88.6% in the year ended December 31, 2006, compared to the year ended December 31, 2005.

 

Sales of cataract procedure packs increased 9.4%, while sales of viscoelastics and cataract equipment grew 8.1% and 2.8%, respectively. Sales of vitreoretinal surgical disposables rose 14.1% and, along with a 9.4% increase in vitreoretinal surgical equipment sales, produced a 12.0% increase in vitreoretinal product sales.

 

Refractive sales declined 8.0% for the year ended December 31, 2006. Refractive technology fees declined by 13.8% and sales of refractive equipment declined in 2006 compared to 2005 as sales of the

This excerpt taken from the ACL 20-F filed Mar 19, 2007.
Natural, the AcrySof® IQ aspheric intraocular lens and the AcrySof® ReSTOR®.

 

The AcrySof® ReSTOR® was approved by the FDA in March 2005. The AcrySof® ReSTOR® is the first and only apodized diffractive intraocular lens for cataract patients with and without presbyopia, providing patients with a full range of quality vision (near, intermediate and distance), and greatly reducing their reliance on glasses. In May 2005, the Centers for Medicare and Medicaid Services clarified Medicare payment rules for presbyopia-correcting intraocular lenses used in cataract surgeries. Prior to this ruling, limitations on Medicare payment and market pricing for presbyopia-correcting intraocular lenses effectively would have prevented beneficiaries from having these lenses implanted. Under the new policy, Medicare will continue existing reimbursement amounts under the covered benefit for cataract surgery, and patients may elect to pay for the non-covered charges for refractive services and presbyopia-correcting intraocular lenses such as the AcrySof® ReSTOR®. Sales of AcrySof® ReSTOR® increased to $54.2 million in 2005, largely due to its U.S. launch in May 2005. U.S. sales of AcrySof® ReSTOR® were $35.3 million, while sales outside the United States were $18.9 million.

 

Total sales of cataract equipment increased 26.2%. Sales of vitreoretinal surgical disposables increased 18.7% and, along with a 21.1% increase in vitreoretinal surgical equipment sales, produced an 18.7% increase in vitreoretinal product sales.

 

58

 

Refractive sales declined 10.5% for the year ended December 31, 2005. Technology fees related to the use of Alcon's CustomCornea® wavefront system increased 11.5% in 2005 over 2004. However, total refractive technology fees declined by 2.2% and sales of refractive equipment declined in 2005 compared to 2004 as sales of the

This excerpt taken from the ACL 6-K filed Apr 25, 2006.
Natural in the global markets. The AcrySof ® ReSTOR® was approved by the FDA in late March 2005. The AcrySof ® ReSTOR® uses a revolutionary apodized diffractive refractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery.

 

As discussed in our annual report on Form 20-F, in May 2005, the Centers for Medicare and Medicaid Services clarified its payment rules to continue existing reimbursement amounts under the covered benefit for cataract surgery, if patients elect to pay for the non-covered charges for refractive services and presbyopia-correcting intraocular lenses such as the AcrySof® ReSTOR®. Largely due to its U.S. launch in May 2005, global sales of AcrySof® ReSTOR® grew to $23.3 million in the three months ended March 31, 2006, compared to $3.2 million for the same period in 2005.

 

Total sales of cataract equipment declined 19.5%, primarily due to lower sales in International markets, while sales of cataract equipment disposables and accessories increased 2.1%. Sales of vitreoretinal surgical disposables increased 13.8% and, along with an 8.8% increase in vitreoretinal surgical equipment sales, produced a 12.8% increase in vitreoretinal product sales.

 

The Company has been a defendant in a lawsuit alleging infringement of two patents owned by Advanced Medical Optics, Inc. ("AMO"). The patent infringement suit by AMO challenged only certain features of Alcon’s Infiniti® vision system and the

This excerpt taken from the ACL 20-F filed Mar 15, 2006.
Natural lens and continued sales growth in other single-piece intraocular lenses.

 

Total cataract equipment sales increased 65.7% in the year ended December 31, 2004 compared to 2003. The primary contributor to this sales growth was the Infiniti® vision system, which was first sold in August of 2003. This tri-modal lens removal system commands a premium price and generated more sales than any of our other surgical equipment products during 2004.

 

Sales of cataract procedure paks, customized and sequenced packages of products required for cataract surgeries, grew 19.5% over 2003.

 

Sales of our refractive products declined by 10.7%. Increased technology fees related to the use of our CustomCornea® wavefront system resulted in an increase in total refractive technology fees for the year ended December 31, 2004 compared to 2003. However, sales of refractive equipment declined in the year ended December 31, 2004 from 2003. Equipment sales in 2003 benefited from the sale of LADARWave® wavefront aberrometers to our existing

This excerpt taken from the ACL 6-K filed Oct 20, 2005.
Natural and AcrySof® ReSTOR®, contributed to the growth in International Surgical sales, along with increased sales of cataract surgical procedure packs. Higher sales of Systane® and
This excerpt taken from the ACL 6-K filed Jul 28, 2005.
Natural and market growth of the AcrySof® ReSTOR®, as discussed earlier.

 

Total sales of cataract equipment increased 21.3%. Sales of vitreous disposables increased 20.9% and, along with a 23.7% increase in vitreous equipment sales, produced a 19.9% increase in vitreoretinal product sales.

 

As discussed in note 13 to the condensed consolidated financial statements, the Company is a defendant in a lawsuit alleging infringement of two patents owned by Advanced Medical Optics Inc. (“AMO”). The patent infringement suit by AMO challenges only certain features of Alcon’s

This excerpt taken from the ACL 6-K filed Apr 22, 2005.
Natural intraocular lenses and vitreous disposables. The increase in United States Consumer Eye Care sales primarily resulted from sales growth of
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki